United States: Capitol Hill Healthcare Update June 26, 2017

Searching for 50 Votes: Changes to Health Bill, CBO Score Coming This Week

Senate Republican leaders are expected to make a series of changes to the healthcare legislation released Thursday as they scramble to gain the support of at least 50 lawmakers in a showdown vote scheduled for later this week.

GOP leaders are expected to offer additional changes on Medicaid, continuous coverage and opioid addiction funding in an effort to entice senators, including five lawmakers who announced their outright opposition and several others who expressed reservations about the draft bill. The Congressional Budget Office also is expected to release its analysis as soon as today, including estimates on insurance coverage and premiums, and the draft bill's impact on government spending.

Senate Majority Leader Mitch McConnell (R-Ky.) this week will try to strike just the right balance of legislative changes to woo moderates and conservatives who oppose the current draft, now called the Better Care Reconciliation Act. It's a tightrope exercise, and it's not clear whether McConnell can succeed. He can only afford to lose two votes from his 52-seat majority.

The Senate will take a procedural vote Wednesday to bring up the bill and then debate the legislation for up to 20 hours, split evenly between the two parties. After that, senators will begin a "vote-a-rama," a series of rapid-fire votes on dozens of amendments in a marathon session that likely could stretch for hours.

GOP leaders will offer their changes to the House-approved bill as one package, called a "manager's amendment." Democrats are expected to offer a series of amendments designed to draw political blood from Republicans, on issues such as restoring insurance regulations and addressing prescription drug prices. Many amendments will never see a vote because the Senate parliamentarian is expected to rule them ineligible to be added to a budget reconciliation bill, which generally can include only provisions that directly impact government spending and taxes.

Will Republicans get the votes they need to pass the bill? That's not currently clear. Some senators who have expressed opposition are expected to ultimately vote for the bill after their policy or state-specific issues are addressed in the manager's amendment. But several key senators say their issues can be addressed only in ways that may undermine the coalition McConnell is trying to assemble.

Will the vote occur this week as McConnell has pledged? All signs point to a vote at the end of the week, even if Republicans don't have the support to pass their revised bill. Some senators, including Sens. Ron Johnson (R-Wis.) and Susan Collins (R-Maine), have said a vote should be delayed until after the Fourth of July recess to allow lawmakers time to understand the bill and its implications – or for additional legislative tweaks and arm-twisting by GOP leaders. But some Republican leadership aides say delaying a vote until mid-July likely wouldn't improve its prospects.

No Democrat is expected to support the bill. But some Republicans speculate that if Sen. Shelly Moore Capito (R-W.Va.) can be persuaded to vote for the bill with certain Medicaid changes and a dramatic boost to opioid addiction funding, Sen. Joe Manchin (D-W.Va.) might vote for it too. Manchin, who has given no public indication he would support the bill, is seeking re-election in 2018 in a state where President Donald Trump received 69 percent of the vote last November.

FDA User Fee Renewal Stalled Until July

With the focus in the Senate on securing votes for Republicans' plans to replace the Affordable Care Act, action on renewing expiring Food and Drug Administration (FDA) user fees is likely to slip until after Congress' Fourth of July recess.

House and Senate committees have approved a five-year renewal of user fees for pharmaceutical and medical device manufacturers, but neither chamber has voted on their bills. Congressional leaders are seeking to avoid a conference committee by harmonizing the legislation before it passes the House and Senate.

The bills that won approval in the Senate HELP and House Energy and Commerce committees do have some differences. But leaders have worked to keep both bills free from controversial language, and committee staff say the differences shouldn't stand in the way of reaching an agreement.

The user fees expire Sept. 30. Without congressional action by Aug. 1, mandatory notices will be sent to FDA staff whose jobs are tied to user fee funding, warning of potential layoffs if Congress fails to renew the program. Lawmakers in both parties say they want to avoid triggering those notices.

Lawmakers Call on VA to Address Payment Backlog

A group of House Republicans is calling on the Department of Veterans Affairs (VA) to address the "alarming amount of late payments" for medical devices in the VA system.

Rep. Jim Banks (R-Ind.) is circulating a draft letter among his colleagues to VA Secretary David Shulkin. Banks, a member of the House Committee on Veterans' Affairs, is planning to finalize the letter this week but so far has nearly four dozen lawmakers who have agreed to sign on.

Banks said some medical device manufacturers have outstanding VA invoices going back as far as 2013, with accounts receivable reaching into the millions of dollars. He said the VA is routinely more than 90 days late on more than one-third of payments for medical devices used in VA healthcare.

Overall, the VA owes as much as $15 million for replacement knees, replacement hips, spine implants, cardiac pacemakers and defibrillators provided through the VA Prosthetics Program, according to the letter.

Republican, Democrat Question Pharma, Insurers on Insulin Costs

The leaders of the Congressional Diabetes Caucus say they are "gravely concerned" about the rising cost of insulin, and they are calling on trade associations representing pharmaceutical manufacturers and insurers to meet with the caucus next month.

Reps. Tom Reed (R-N.Y.) and Diana DeGette (D-Colo.), the co-chairs of the caucus, said the average price of insulin tripled between 2002 and 2013, and many patients are facing high payments due to high deductibles, co-insurance and formulary exclusions.

They requested meetings on July 28 with the Pharmaceutical Research and Manufacturers of America, the Pharmaceutical Care Management Association and America's Health Insurance Plans. The lawmakers said Congress may need to step in to stabilize insulin prices but first they want to hear from stakeholders.

Lawmakers Call for Relief from DME Competitive Bidding

More than 150 House lawmakers are calling on the U.S. Department of Health and Human Services (HHS) to provide relief from the Center for Medicare and Medicaid Services' (CMS') recently enacted competitively bid rates in rural areas for durable medical equipment.

In a letter to HHS Secretary Tom Price, the lawmakers said CMS' action is coming at the expense of Medicare beneficiaries and shifting costs to institutional and clinical care.

Sent by a group led by House Republican Conference Chairwoman Cathy McMorris Rodgers (R-Wash.), the letter calls on Price to provide relief for non-competitive bid areas, which are primarily rural communities. The lawmakers also call for changes to the overall program before the next scheduled round of competitive bidding in 2019.

When he served in the House, Price was an outspoken opponent of DME competitive bidding.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.